A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)
- Registration Number
- NCT04583423
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis of the study is that at least 1 dose of MK-3655 is superior to placebo with respect to the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 183
- Has histological confirmation of NASH
- Is a male or female aged 18 years to 80 years (in Japan and Taiwan aged 20 to 80 years)
- Has a body mass index (BMI) ≥25 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
- Has no history of Type 2 diabetes mellitus (T2DM) OR a history of T2DM controlled by diet or stable doses of antihyperglycemic agents (AHAs)
- Contraceptive use by male participants should be consistent with local regulations.
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and she is not a woman of child-bearing potential (WOCBP) OR she is a WOCBP and uses a contraceptive method that is highly effective during the intervention period and for at least 16 weeks after the last dose of study intervention.
Exclusion Criteria
- Has presence of cirrhosis on liver biopsy
- Has Type 1 diabetes
- Has a history of malignancy, unless cancer free ≥5 years, or is under evaluation for active or suspected malignancy except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- Has a history of bariatric surgery ≤5 years before study participation
- Has undergone a major surgical procedure ≤3 months before study participation or has major surgery planned during the study
- Has a history or evidence of chronic liver disease other than NASH. Individuals with a history of Hepatitis B or C may be eligible for participation.
- Has significant systemic or major illnesses other than liver disease, including recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, arterial revascularization, pulmonary disease, renal failure, stroke, transient ischemic attack, or organ transplantation
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description MK-3655 50 mg MK-3655 Following a 2-week placebo run-in, participants will receive MK-3655 50 mg by subcutaneous (SC) injection once every 4 weeks (Q4W) for 52 weeks. MK-3655 100 mg MK-3655 Following a 2-week placebo run-in, participants will receive MK-3655 100 mg by SC injection Q4W for 52 weeks. Placebo Placebo Following a 2-week placebo run-in, participants will receive Placebo by SC injection Q4W for 52 weeks. MK-3655 300 mg MK-3655 Following a 2-week placebo run-in, participants will receive MK-3655 300 mg by SC injection Q4W for 52 weeks.
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Experienced an Adverse Event (AE) Up to 64 weeks An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
Percentage of Participants Discontinuing Study Medication Due to an AE Up to 52 weeks An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study.
Percentage of Participants With Nonalcoholic Steatohepatitis (NASH) Resolution Without Worsening of Fibrosis After 52 Weeks Week 52 The NASH Clinical Research Network (CRN) scoring system evaluated by Blinded Independent Central Review (BICR) was used to assess treatment response. The NASH CRN scoring scales were: lobular inflammation score (0-3); hepatocyte ballooning score (0-2); steatosis score (0-3); and fibrosis score (0-4). NASH resolution was defined as a score of 0-1 for inflammation, 0 for ballooning, and any grade of steatosis.
- Secondary Outcome Measures
Name Time Method Mean Percent Relative Reduction From Baseline in Liver Fat Content (LFC) After 24 Weeks Baseline and Week 24 LFC % was measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) and evaluated by BICR. MRI-PDFF is a highly accurate noninvasive measure of the proportion of fat content of a tissue.
Percentage of Participants With ≥2 Point Improvement in NAS With ≥1 Point Improvement in Inflammation or Ballooning Without Worsening of Fbrosis by Histology (Evaluated by BICR) After 52 Weeks Week 52 Participants with ≥2 point improvement in the NAS with ≥1 point improvement in inflammation or ballooning without worsening of fibrosis were assessed with the NASH CRN scoring system (evaluated by BICR). The NAS was calculated as the unweighted sum of the scores and ranges from 0-8 (highest activity).
Percentage of Participants With ≥1 Stage Improvement in Fibrosis Without Worsening of Steatohepatitis Assessed With the NASH CRN Scoring System After 52 Weeks Week 52 Participants were evaluated with the NASH CRN scoring system with BICR with ≥1 stage improvement in fibrosis without worsening of steatohepatitis defined as no increase in the ballooning, inflammation, or steatosis scores.
Trial Locations
- Locations (180)
Del Sol Research Management ( Site 2674)
🇺🇸Tucson, Arizona, United States
Adobe Clinical Research, LLC ( Site 2644)
🇺🇸Tucson, Arizona, United States
Hope Clinical Research, Inc. ( Site 2601)
🇺🇸Canoga Park, California, United States
Legacy Clinical Solutions: Tandem Clinical Research, LLC ( Site 2650)
🇺🇸Marrero, Louisiana, United States
A.P.H. Paris, Hopital Saint Antoine ( Site 0807)
🇫🇷Paris, France
Hiroshima University Hospital ( Site 1413)
🇯🇵Hiroshima, Japan
Kagawa Prefectural Central Hospital-liver intemal medicine ( Site 1416)
🇯🇵Takamatsu, Kagawa, Japan
Shinyurigaoka General Hospital ( Site 1420)
🇯🇵Kawasaki, Kanagawa, Japan
Kanazawa University Hospital ( Site 1419)
🇯🇵Kanazawa, Ishikawa, Japan
Taichung Veterans General Hospital ( Site 2306)
🇨🇳Taichung, Taiwan
Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi ( Site 2400)
🇹🇷Istanbul, Turkey
National Taiwan University Hospital ( Site 2301)
🇨🇳Taipei, Taiwan
National Cheng Kung University Hospital ( Site 2304)
🇨🇳Tainan, Taiwan
Ankara University Cebeci Research and Application Hospital ( Site 2406)
🇹🇷Ankara, Turkey
Kawasaki Medical School General Medical Center ( Site 1412)
🇯🇵Okayama, Japan
Hacettepe Uni. Ic Hastaliklari Anabilim Dali, Nefroloji BD ( Site 2403)
🇹🇷Ankara, Turkey
Istanbul Universitesi Tip Fakultesi Hastanesi ( Site 2401)
🇹🇷Istanbul, Turkey
Surgical Clinic "Parada" ( Site 1921)
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
Gazi University Medical Faculty ( Site 2405)
🇹🇷Ankara, Turkey
Chang Gung Memorial Hospital - Linkou Branch ( Site 2305)
🇨🇳Taoyuan County, Taoyuan, Taiwan
Centre Hospitalier et Universitaire Dupuytren ( Site 0810)
🇫🇷Limoges, Haute-Vienne, France
C.H.U. Nancy Hopital de Brabois ( Site 0803)
🇫🇷Vandoeuvre les Nancy, Meurthe-et-Moselle, France
Hospital San Juan de Dios de La Serena ( Site 0500)
🇨🇱La Serena, Coquimbo, Chile
GIRI GI Research Institute - Vancouver ( Site 0404)
🇨🇦Vancouver, British Columbia, Canada
Hôpital Beaujon ( Site 0804)
🇫🇷Clichy, Hauts-de-Seine, France
Clinical Research Chile SpA ( Site 0506)
🇨🇱Valdivia, Los Rios, Chile
Enroll SpA ( Site 0508)
🇨🇱Santiago, Region M. De Santiago, Chile
Centro de Investigaciones Clinicas Vina del Mar ( Site 0502)
🇨🇱Vina del Mar, Valparaiso, Chile
CHU de Nice Hopital de l Archet II ( Site 0800)
🇫🇷Nice, Alpes-Maritimes, France
Hopital Henri Mondor ( Site 0808)
🇫🇷Creteil, Val-de-Marne, France
Centro de Investigacion Medica de Occidente S.C. ( Site 1514)
🇲🇽Zapopan, Jalisco, Mexico
Fundacion Santa Fe de Bogota ( Site 0705)
🇨🇴Bogotá, Distrito Capital De Bogota, Colombia
Medical Care and Research S.A. de C.V. ( Site 1506)
🇲🇽Merida, Yucatan, Mexico
Azienda Ospedaliera Universitaria Integrata Verona ( Site 1301)
🇮🇹Verona, Italy
Ege University Medical Faculty ( Site 2404)
🇹🇷Izmir, Turkey
Nephrology Clinic of Internal and Prof. Diseases n.a.E.M.Tareev ( Site 1906)
🇷🇺Moscow, Moskva, Russian Federation
Center targetnoy therapy-Gastroenterology ( Site 1918)
🇷🇺Moscow, Moskva, Russian Federation
Scientific research center ECO-security ( Site 1920)
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
St George Hospital ( Site 0104)
🇦🇺Kogarah, New South Wales, Australia
Velocity Clinical Research, Huntington Park ( Site 9022)
🇺🇸Huntington Park, California, United States
Arizona Liver Health ( Site 9026)
🇺🇸Tucson, Arizona, United States
UCSD - Altman Clinical and Translational Research Institute -UC San Diego NAFLD Research Center ( Si
🇺🇸La Jolla, California, United States
Arkansas Gastroenterology - North Little Rock ( Site 9015)
🇺🇸North Little Rock, Arkansas, United States
Catalina Research Institute, LLC ( Site 2643)
🇺🇸Montclair, California, United States
Velocity Clinical Research, Panorama City ( Site 9001)
🇺🇸Panorama City, California, United States
Top Medical Research, Inc ( Site 2673)
🇺🇸Cutler Bay, Florida, United States
Peak Gastroenterology Associates ( Site 2645)
🇺🇸Colorado Springs, Colorado, United States
Ocean Blue Medical Research Center Inc ( Site 2667)
🇺🇸Miami Springs, Florida, United States
Southeast Clinical Research Center ( Site 9003)
🇺🇸Dalton, Georgia, United States
Sensible Healthcare Llc ( Site 2607)
🇺🇸Ocoee, Florida, United States
The University of Iowa ( Site 2655)
🇺🇸Iowa City, Iowa, United States
The National Diabetes & Obesity Research Institute ( Site 9017)
🇺🇸Biloxi, Mississippi, United States
NYU Langone Health, New York ( Site 2627)
🇺🇸New York, New York, United States
Hillmont G.I. ( Site 9019)
🇺🇸Flourtown, Pennsylvania, United States
DHR Health Institute for Research and Development ( Site 9006)
🇺🇸Edinburg, Texas, United States
Regional Gastroenterology Associates of Lancaster, LTD ( Site 9020)
🇺🇸Lancaster, Pennsylvania, United States
Premier Medical Group ( Site 9010)
🇺🇸Clarksville, Tennessee, United States
Regional Gastroenterology Associates of Lancaster, LTD ( Site 9004)
🇺🇸Wyomissing, Pennsylvania, United States
South Texas Research Institute ( Site 9012)
🇺🇸Edinburg, Texas, United States
Impact Research Institute ( Site 2685)
🇺🇸Waco, Texas, United States
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0010)
🇦🇷Mar del Plata, Buenos Aires, Argentina
DIM Clínica Privada ( Site 0011)
🇦🇷Ramos Mejía, Buenos Aires, Argentina
Hospital Británico de Buenos Aires ( Site 0002)
🇦🇷Buenos Aires, Caba, Argentina
Hospital Universitario Austral ( Site 0003)
🇦🇷Pilar, Buenos Aires, Argentina
Glenny Corp. S.A.-CLINICAL RESEARCH ( Site 0013)
🇦🇷Buenos Aires, Caba, Argentina
Hospital Italiano de Buenos Aires-Hepatology ( Site 0014)
🇦🇷Ciudad de Buenos Aires, Caba, Argentina
Clinica de nefrologia urologia y enfermedades cardiovasculares ( Site 0008)
🇦🇷Santa Fe, Argentina
Hospital Aleman ( Site 0009)
🇦🇷Buenos Aires, Argentina
Flinders Medical Centre ( Site 0107)
🇦🇺Bedford Park, South Australia, Australia
McGill University Health Centre ( Site 0400)
🇨🇦Montréal, Quebec, Canada
Hospital Regional de Concepcion ( Site 0505)
🇨🇱Concepcion, Biobio, Chile
Beijing YouAn Hospital, Capital Medical University ( Site 0605)
🇨🇳Beijing, Beijing, China
Pontificia Universidad Catolica de Chile ( Site 0501)
🇨🇱Santiago, Region M. De Santiago, Chile
Chongqing Three Gorges Central Hospital ( Site 0618)
🇨🇳Wanzhou District, Chongqing, China
General Hospital of Ningxia Medical University ( Site 0607)
🇨🇳Yinchuan City, Ningxia, China
The First People's Hospital of Foshan-Infection Department ( Site 0612)
🇨🇳Foshan, Guangdong, China
Xinhua Hospital Affiliated to Jiaotong University School of Medicine ( Site 0602)
🇨🇳Shanghai, Shanghai, China
The Affiliated Hospital of Hangzhou Normal University ( Site 0600)
🇨🇳Hangzhou, Zhejiang, China
hopital haut leveque chu de bordeaux-Service d'Hépato-gastroentérologie ( Site 0805)
🇫🇷Pessac, Aquitaine, France
Hopital de la Croix-Rousse ( Site 0809)
🇫🇷Lyon, Auvergne, France
CHU Dijon Bourgogne - Hopital F. Mitterrand ( Site 0816)
🇫🇷Dijon, Bourgogne, France
CHU Besançon ( Site 0806)
🇫🇷Besançon, Franche-Comte, France
Hôpital Claude Huriez ( Site 0811)
🇫🇷Lille, Nord, France
Hopital de la Pitie Salpetriere ( Site 0813)
🇫🇷Paris, France
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0812)
🇫🇷Paris, France
Universitätsklinikum Frankfurt-Medizinische Klinik 1 ( Site 0445)
🇩🇪Frankfurt, Hessen, Germany
Universitaetsklinikum Freiburg ( Site 0446)
🇩🇪Freiburg, Baden-Wurttemberg, Germany
Charite Universitaetsmedizin Berlin ( Site 0443)
🇩🇪Berlin, Germany
Johannes Gutenberg Universitat Mainz ( Site 0442)
🇩🇪Mainz, Rheinland-Pfalz, Germany
Universitaetsklinikum Leipzig ( Site 0447)
🇩🇪Leipzig, Sachsen, Germany
Hippokration University Hopsital-4th Department of Internal Medicine ( Site 3300)
🇬🇷Thessaloniki, Kentriki Makedonia, Greece
Rambam Medical Center ( Site 1201)
🇮🇱Haifa, Israel
Carmel Medical Center ( Site 1203)
🇮🇱Haifa, Israel
Shaare Zedek Medical Center ( Site 1205)
🇮🇱Jerusalem, Israel
Rabin Medical Center ( Site 1204)
🇮🇱Petah Tikva, Israel
Chaim Sheba Medical Center ( Site 1200)
🇮🇱Ramat Gan, Israel
A O U Policlinico di Modena ( Site 1307)
🇮🇹Modena, Italy
Maccabi Health Services - Ramat Hasharon ( Site 1206)
🇮🇱Ramat Hasharon, Israel
Sourasky Medical Center ( Site 1202)
🇮🇱Tel Aviv, Israel
IRCCS Istituto Clinico Humanitas di Rozzano ( Site 1303)
🇮🇹Rozzano, Lombardia, Italy
Ehime University Hospital ( Site 1417)
🇯🇵Toon, Ehime, Japan
Azienda Ospedaliera Policlinico Umberto I ( Site 1300)
🇮🇹Roma, Italy
Aichi Medical University Hospital ( Site 1402)
🇯🇵Nagakute, Aichi, Japan
Ogaki Municipal Hospital ( Site 1409)
🇯🇵Ogaki, Gifu, Japan
Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital ( Site 1404)
🇯🇵Sapporo, Hokkaido, Japan
Kagawa University Hospital ( Site 1414)
🇯🇵Kita-gun, Kagawa, Japan
Nara Medical University Hospital ( Site 1407)
🇯🇵Kashihara, Nara, Japan
Yokohama City University Hospital ( Site 1411)
🇯🇵Yokohama, Kanagawa, Japan
Saiseikai Suita Hospital ( Site 1403)
🇯🇵Suita, Osaka, Japan
Fukui-ken Saiseikai Hospital ( Site 1410)
🇯🇵Fukui, Japan
Gifu Municipal Hospital ( Site 1408)
🇯🇵Gifu, Japan
Kagoshima University Hospital ( Site 1418)
🇯🇵Kagoshima, Japan
University Hospital, Kyoto Prefectural University of Medicine ( Site 1405)
🇯🇵Kyoto, Japan
Osaka Metropolitan University Hospital ( Site 1415)
🇯🇵Osaka, Japan
Toranomon Hospital ( Site 1401)
🇯🇵Tokyo, Japan
Seoul National University Bundang Hospital-Internal Medicine ( Site 2005)
🇰🇷Seongnam, Kyonggi-do, Korea, Republic of
Pusan National University Hospital-Internal Medicine ( Site 2010)
🇰🇷Busan, Pusan-Kwangyokshi, Korea, Republic of
Chungang University Hospital ( Site 2007)
🇰🇷Dongjak-gu, Seoul, Korea, Republic of
Asan Medical Center ( Site 2001)
🇰🇷Songpagu, Seoul, Korea, Republic of
Inha University Hospital-Gastroenterolgy/Hepatology ( Site 2006)
🇰🇷Incheon, Korea, Republic of
Seoul National University Hospital ( Site 2003)
🇰🇷Seoul, Korea, Republic of
Hanyang University Seoul Hospital ( Site 2002)
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center-Gastroenterology/Internal Medicine ( Site 2008)
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital ( Site 2004)
🇰🇷Seoul, Korea, Republic of
Hospital Kuala Lumpur-Gastroenterology Department ( Site 2701)
🇲🇾Kuala Lumpur, Malaysia
Medica Sur-Clinica de Enfermedades Digestivas y Obesidad ( Site 1515)
🇲🇽Mexico City, Distrito Federal, Mexico
Centro de Investigacion Medico Biologica y Terapia Avanzada SC ( Site 1511)
🇲🇽Guadalajara, Jalisco, Mexico
Middlemore Clinical Trials ( Site 1601)
🇳🇿Auckland, New Zealand
Auckland Clinical Studies Limited ( Site 1600)
🇳🇿Auckland, New Zealand
Centro de Investigacion y Gastroenterologia SC ( Site 1503)
🇲🇽Mexico City, Mexico
Christchurch Hospital ( Site 1602)
🇳🇿Christchurch, Canterbury, New Zealand
Pan American Center for Oncology Trials ( Site 3102)
🇵🇷Rio Piedras, Puerto Rico
Klinical Investigations Group ( Site 3100)
🇵🇷San Juan, Puerto Rico
Russian University of People Friendship ( Site 1907)
🇷🇺Moscow, Moskva, Russian Federation
City Clinical Hospital named V.M.Buyanova ( Site 1922)
🇷🇺Moscow, Moskva, Russian Federation
Medical Rehabilitation Center ( Site 1904)
🇷🇺Moscow, Moskva, Russian Federation
Hospital Universitario Marqués de Valdecilla-Gastroenterology and Hepatology ( Site 2106)
🇪🇸Santander, Cantabria, Spain
LLC Astarta ( Site 1912)
🇷🇺Saint Petersburg, Sankt-Peterburg, Russian Federation
SPb State Budgetary Institution Health Care City Policlinic 17 ( Site 1910)
🇷🇺St -Petersburg, Sankt-Peterburg, Russian Federation
Hospital Universitari Vall d Hebron ( Site 2101)
🇪🇸Barcelona, Spain
Hospital Universitario Puerta de Hierro-Majadahonda ( Site 2100)
🇪🇸Majadahonda, Madrid, Spain
Hospital Clinic de Barcelona ( Site 2102)
🇪🇸Barcelona, Spain
Hospital Clinico Universitario de Santiago ( Site 2104)
🇪🇸Santiago de Compostela, La Coruna, Spain
Karolinska Universitetssjukhuset Huddinge ( Site 2900)
🇸🇪Huddinge, Stockholms Lan, Sweden
Hospital Universitario Virgen del Rocio ( Site 2105)
🇪🇸Sevila, Sevilla, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 2302)
🇨🇳Kaohsiung, Taiwan
Akademiska sjukhuset ( Site 2901)
🇸🇪Uppsala, Uppsala Lan, Sweden
Chung Shan Medical University Hospital ( Site 2307)
🇨🇳Taichung City, Taichung, Taiwan
Chiayi Christian Hospital ( Site 2308)
🇨🇳Chiayi City, Chiayi, Taiwan
Bezmialem Vakf Üniversitesi-Gastroenterology ( Site 2402)
🇹🇷Istanbul, Turkey
FDI Clinical Research ( Site 3101)
🇵🇷San Juan, Puerto Rico
Velocity Clinical Research, Westlake ( Site 9013)
🇺🇸Los Angeles, California, United States
Covenant Metabolic Specialists, LLC ( Site 9027)
🇺🇸Fort Myers, Florida, United States
Genoma Research Group, Inc. ( Site 2669)
🇺🇸Miami, Florida, United States
Ruane Clinical Research Group, Inc ( Site 9014)
🇺🇸Los Angeles, California, United States
Quest Clinical Research ( Site 9011)
🇺🇸San Francisco, California, United States
Velocity Clinical Research, Santa Ana ( Site 9002)
🇺🇸Santa Ana, California, United States
Sweet Hope Research Specialty Inc ( Site 2660)
🇺🇸Hialeah, Florida, United States
Synexus Research ( Site 2672)
🇺🇸Orlando, Florida, United States
Indago Research and Health Center Inc ( Site 2610)
🇺🇸Hialeah, Florida, United States
Royal Prince Alfred Hospital ( Site 0102)
🇦🇺Camperdown, New South Wales, Australia
Floridian Clinical Research, LLC ( Site 2656)
🇺🇸Miami Lakes, Florida, United States
Kansas City Research Institute ( Site 9018)
🇺🇸Kansas City, Missouri, United States
Excel Clinical Research, LLC ( Site 2603)
🇺🇸Las Vegas, Nevada, United States
Velocity Clinical Research, Syracuse ( Site 9016)
🇺🇸East Syracuse, New York, United States
Texas Clinical Research Institute ( Site 2619)
🇺🇸Arlington, Texas, United States
The Liver Institute at Methodist Dallas Medical Center ( Site 2638)
🇺🇸Dallas, Texas, United States
Baylor College of Medicine - Advanced Liver Therapies ( Site 2670)
🇺🇸Houston, Texas, United States
The Crofoot Research Center, Inc. ( Site 2611)
🇺🇸Houston, Texas, United States
Quality Research ( Site 9024)
🇺🇸San Antonio, Texas, United States
American Research Corporation at Texas Liver Institute ( Site 2634)
🇺🇸San Antonio, Texas, United States
Clinical Trials of Texas, LLC ( Site 2614)
🇺🇸San Antonio, Texas, United States
Virginia Commonwealth University Health System ( Site 2657)
🇺🇸Richmond, Virginia, United States
University Health Network - Toronto General Hospital ( Site 0401)
🇨🇦Toronto, Ontario, Canada
North Florida South Georgia Veterans Health System ( Site 2613)
🇺🇸Gainesville, Florida, United States
California Liver Research Institute ( Site 9025)
🇺🇸Pasadena, California, United States
Hospital Provincial del Centenario ( Site 0007)
🇦🇷Rosario, Santa Fe, Argentina
Prince of Wales Hospital ( Site 1001)
🇭🇰Shatin, Hong Kong
Queen Mary Hospital ( Site 1003)
🇭🇰Hong Kong, Hong Kong
Prince of Wales Hospital ( Site 1002)
🇭🇰Shatin, Hong Kong